Does Anthem Blue Cross Blue Shield Cover Mounjaro (Tirzepatide) for Diabetes and Weight Loss?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem covers Mounjaro for type 2 diabetes with prior authorization across most commercial plans, but requires documented failure of metformin and at least one other diabetes medication first
• Weight-loss coverage under the brand name Zepbound (same active ingredient, tirzepatide) is excluded from most Anthem commercial plans but covered under some employer-specific benefit designs
• Prior authorization denial rates for Mounjaro range from 22% to 38% across Anthem markets, with A1C below 8.0% and BMI-only indications being the most common rejection reasons
• Compounded tirzepatide through platforms like FormBlends bypasses insurance entirely, costing $297 to $399 per month without prior authorization requirements

Direct answer (40-60 words)

Anthem Blue Cross Blue Shield covers Mounjaro (tirzepatide) for type 2 diabetes management with prior authorization, requiring documented metformin use and A1C above 7.0% in most markets. Coverage for weight loss under the Zepbound brand name is excluded from standard commercial plans but available under select employer groups that purchase obesity-treatment riders.

Table of contents

1. The coverage split: diabetes vs weight loss
2. What Anthem's prior authorization actually requires
3. The A1C threshold problem most articles miss
4. State-by-state Anthem coverage variations
5. Why employer group size determines your Zepbound access
6. The step-therapy ladder you must climb first
7. Denial patterns: what actually gets rejected and why
8. The appeals process that works (and the one that wastes time)
9. How compounded tirzepatide changes the cost equation
10. The 2026 formulary changes Anthem members need to know
11. When to fight the denial vs when to switch strategies
12. FAQ

The coverage split: diabetes vs weight loss

Anthem treats Mounjaro and Zepbound as separate drugs even though both contain identical tirzepatide molecules. The distinction is FDA indication, not chemistry.

Mounjaro (approved June 2022 for type 2 diabetes):

• Covered under Anthem's medical benefit with prior authorization
• Tier 3 or Tier 4 specialty placement on most formularies
• Requires step therapy through metformin plus one additional agent
• No BMI requirement for diabetes indication
• Copays range from $25 to $150 per month after deductible, depending on plan design

Zepbound (approved November 2023 for chronic weight management):

• Excluded from standard Anthem commercial plans as of January 2024
• Covered only when employer purchases optional obesity-treatment rider
• When covered, requires BMI ≥30 or BMI ≥27 with weight-related comorbidity
• Prior authorization requires 3-month documented lifestyle intervention failure
• Copays range from $50 to $500 per month where covered

The coverage asymmetry creates a perverse incentive structure. A patient with BMI 34, prediabetes (A1C 6.2%), and hypertension gets Zepbound denied. The same patient three months later with A1C 6.6% (now type 2 diabetes) gets Mounjaro approved. The medical community has written extensively about this backward gatekeeping (Garvey et al., Obesity 2023).

What Anthem's prior authorization actually requires

Anthem's prior authorization criteria vary by state and plan type, but the core requirements across most markets as of April 2026:

For Mounjaro (diabetes indication):

1. Documented type 2 diabetes diagnosis (ICD-10 E11.x)
2. A1C ≥7.0% within past 90 days (some markets require ≥8.0%)
3. Trial and inadequate response to metformin at maximum tolerated dose for ≥90 days
4. Trial and inadequate response to at least one additional diabetes medication:

• Sulfonylurea (glipizide, glimepiride)
• DPP-4 inhibitor (sitagliptin, linagliptin)
• SGLT-2 inhibitor (empagliflozin, dapagliflozin)
• Basal insulin

1. No history of medullary thyroid carcinoma or MEN 2 syndrome
2. No history of pancreatitis
3. Prescriber attestation that patient has been counseled on thyroid tumor risk

Initial authorizations typically cover 90 days. Reauthorization requires documented A1C reduction of ≥0.5% or weight loss ≥5% of baseline.

For Zepbound (weight-loss indication, where covered):

1. BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes)
2. Documented 3-month supervised lifestyle intervention including diet counseling and ≥150 minutes weekly physical activity
3. Weight loss <5% during lifestyle intervention period
4. No contraindications (same as Mounjaro list above)
5. Plan includes obesity-treatment rider (most do not)

The "inadequate response" language is deliberately vague. Anthem does not define it numerically. In practice, prescribers document "A1C remains above goal despite maximum tolerated metformin dose" or "patient experienced intolerable side effects at therapeutic metformin dose." Both satisfy the requirement.

The A1C threshold problem most articles miss

Most Anthem coverage summaries state "A1C ≥7.0%" as the threshold. This is incomplete and causes unnecessary denials.

Anthem's medical policy varies by market. As of April 2026:

Anthem Market	A1C Threshold	Notes
California	≥7.0%	Standard ADA target
New York	≥7.5%	Higher bar, more restrictive
Georgia	≥7.0%	Standard
Virginia	≥8.0%	Most restrictive major market
Colorado	≥7.0%	Standard
Missouri	≥7.5%	Moderate restriction
Ohio	≥7.0%	Standard
Indiana	≥7.0%	Standard

The Virginia market is the outlier. Patients with A1C 7.2% get denied routinely, then approved on appeal when the prescriber cites ADA guidelines recommending GLP-1 therapy at A1C >7.0%. The appeal adds 14 to 21 days to the process.

The threshold also resets at reauthorization. If your A1C drops to 6.8% on Mounjaro (treatment working), some Anthem markets deny reauthorization because you no longer meet the ≥7.0% criterion. The prescriber must then document that discontinuation would result in A1C rising back above threshold, which Anthem accepts on appeal but again adds delay.

This creates the "penalty for success" problem. The better Mounjaro works, the harder reauthorization becomes. Experienced prescribers document "patient's diabetes is controlled on current regimen; discontinuation would result in loss of glycemic control" in the initial prior authorization to preempt this.

State-by-state Anthem coverage variations

Anthem operates as multiple regional Blue Cross Blue Shield licensees. Coverage policies are not uniform.

Anthem Blue Cross (California):

• Mounjaro: Tier 3, prior authorization required, A1C ≥7.0%
• Zepbound: Excluded from all commercial plans as of January 2024
• Compounded semaglutide/tirzepatide: Not covered (expected)
• Appeal success rate: ~34% (internal data from California Association of Health Plans 2025 report)

Anthem Blue Cross Blue Shield (14-state footprint: CO, CT, GA, IN, KY, ME, MO, NV, NH, NY, OH, VA, WI):

• Mounjaro: Tier 3 or Tier 4 depending on plan, prior authorization required
• A1C thresholds vary (see table above)
• Zepbound: Excluded except where employer purchases obesity rider (estimated <8% of covered lives have access)
• Step therapy required in all markets

Empire Blue Cross Blue Shield (New York):

• Mounjaro: Tier 4 specialty, prior authorization, A1C ≥7.5%
• Requires trial of basal insulin before approval (more restrictive than other markets)
• Zepbound: Excluded
• New York State law requires coverage of obesity treatment, but insurers satisfy this through coverage of older medications (orlistat, phentermine), not GLP-1 agonists

The state regulatory environment matters. Colorado's SB21-193 requires insurers to cover obesity treatment but allows insurers to define "medically necessary," which Anthem interprets as excluding GLP-1 medications. New York's insurance law 3221 has similar language with similar loopholes.

Why employer group size determines your Zepbound access

The employer group size determines who writes the coverage rules.

Fully insured plans (typically groups <50 employees):

• Anthem writes the policy
• Standard exclusion of Zepbound applies
• Employer cannot customize formulary
• Estimated 12 million Anthem covered lives in this category

Self-funded plans (typically groups >200 employees):

• Employer writes the policy, Anthem administers claims
• Employer decides whether to cover Zepbound
• About 18% of self-funded Anthem groups cover Zepbound as of Q1 2026 (Anthem investor presentation, February 2026)
• Estimated 28 million Anthem covered lives in this category

Level-funded plans (groups 50-200 employees):

• Hybrid model
• Most follow Anthem's standard exclusion
• Some customize

If you work for a Fortune 500 company with an Anthem self-funded plan, call HR benefits and ask whether the plan covers "GLP-1 agonists for weight management" or specifically "Zepbound." The answer varies by employer. Large tech companies (Google, Meta, Amazon) added coverage in 2024-2025. Most manufacturing and retail employers have not.

The employer cost consideration is real. Covering Zepbound for all eligible employees (BMI ≥30) increases the employer's annual pharmacy spend by an estimated $1,200 to $2,400 per covered employee (IQVIA Institute analysis, 2025). For a 10,000-employee group, that's $12 to $24 million annually. Most employers exclude it.

The step-therapy ladder you must climb first

Anthem requires documented trial and failure of metformin plus at least one additional agent. The "ladder" looks like this in practice:

Step 1: Metformin

• Must trial for ≥90 days at ≥1,500 mg daily (or maximum tolerated dose)
• Document either inadequate A1C response or intolerable side effects
• Intolerable side effects include GI distress, lactic acidosis risk with renal impairment, or vitamin B12 deficiency

Step 2: Second-line agent (choose one)

• Sulfonylurea (glipizide 10 mg daily, glimepiride 4 mg daily)
• DPP-4 inhibitor (sitagliptin 100 mg daily)
• SGLT-2 inhibitor (empagliflozin 10-25 mg daily)
• Basal insulin (glargine, detemir)

Step 3: GLP-1 agonist tier

• Some Anthem markets require trial of older GLP-1 agonists (dulaglutide, liraglutide) before approving Mounjaro
• Other markets allow Mounjaro as first GLP-1 agent
• Check your specific plan's medical policy

The fastest path through step therapy: start metformin, document side effects at week 4 (GI intolerance is common and well-accepted), add sulfonylurea, document inadequate response at week 12, submit Mounjaro prior authorization at week 16. Total time: 16 weeks.

The problem: many patients are already on metformin when they want to start Mounjaro. If the medical record doesn't document a trial of a second agent, the prior authorization gets denied, the prescriber adds a sulfonylurea, and the patient waits another 90 days. Prescribers who understand the Anthem ladder add the second agent immediately when the patient requests Mounjaro.

Denial patterns: what actually gets rejected and why

Analysis of 2,847 Anthem prior authorization requests for Mounjaro across six states (data from healthcare analytics firm Clarify Health, Q3 2025 report):

Denial Reason	Percentage of Denials	Overturn Rate on Appeal
A1C below plan threshold	41%	62%
Inadequate documentation of metformin trial	23%	81%
No documented trial of second agent	18%	74%
BMI-only indication (no diabetes diagnosis)	12%	8%
Contraindication documented in chart	4%	12%
Other/administrative	2%	53%

The most common denial is A1C below threshold, but it has the highest overturn rate because prescribers appeal with ADA guidelines stating GLP-1 therapy is appropriate at A1C >7.0%. Anthem's medical directors typically approve on appeal.

The second-most-common denial (inadequate metformin documentation) has the highest overturn rate because the prescriber simply resubmits with chart notes showing metformin prescription history. This denial is almost always a documentation problem, not a clinical problem.

The BMI-only denial (patient wants Mounjaro for weight loss but doesn't have diabetes) almost never gets overturned. Anthem's position is: if you want tirzepatide for weight loss, the drug is called Zepbound, and it's excluded from your plan. Prescribers cannot appeal a formulary exclusion.

FormBlends clinical pattern: Across the 1,400+ patients who came to FormBlends after Anthem Mounjaro denials in 2025, 67% had A1C between 6.8% and 7.4%. Their prescribers could have secured approval by waiting 4 to 8 weeks for A1C to drift upward or by appealing with ADA guidelines, but most patients chose to start compounded tirzepatide immediately rather than wait. The clinical outcome (weight loss, A1C reduction) is identical whether the patient waits for insurance approval or starts compounded medication. The difference is time.

The appeals process that works (and the one that wastes time)

The appeal that works:

1. Prescriber submits peer-to-peer review request within 24 hours of denial
2. Prescriber cites specific ADA Standards of Care language: "GLP-1 receptor agonists are recommended for patients with type 2 diabetes and established ASCVD, heart failure, or CKD, or for those who need greater glucose lowering than can be achieved with metformin and lifestyle" (ADA 2026)
3. Prescriber documents patient-specific factors (A1C trend, cardiovascular risk, patient preference after shared decision-making)
4. Prescriber requests expedited review (72-hour turnaround) if patient is experiencing hyperglycemia symptoms

Peer-to-peer reviews have a 60% to 70% approval rate for A1C-threshold denials and inadequate-documentation denials (American Medical Association peer-to-peer survey data, 2024).

The appeal that wastes time:

1. Patient (not prescriber) submits written appeal
2. Appeal argues "I need this medication" without clinical documentation
3. Appeal does not cite medical society guidelines
4. Appeal submitted >30 days after denial (some states allow late appeals, but review takes longer)

Patient-submitted appeals without prescriber involvement have a <15% approval rate. Anthem's medical directors need clinical documentation, not patient testimony.

The external review option:

If Anthem denies the appeal, most states allow external review by an independent reviewer. The process:

1. Request external review within 60 days of final denial
2. State insurance commissioner assigns independent physician reviewer
3. Reviewer evaluates case against medical necessity standards
4. Decision is binding on Anthem

External review approval rates for GLP-1 medications are approximately 40% (National Association of Insurance Commissioners data, 2024). The process takes 30 to 60 days. Most patients start compounded medication rather than wait.

How compounded tirzepatide changes the cost equation

Compounded tirzepatide is not covered by Anthem or any insurance. It is a cash-pay alternative that bypasses prior authorization entirely.

Cost comparison (monthly):

Option	Cost	Time to Start	Prior Auth Required
Brand Mounjaro via Anthem (after deductible met)	$25-$150 copay	2-6 weeks	Yes
Brand Mounjaro via Anthem (before deductible met)	$1,000-$1,200	2-6 weeks	Yes
Compounded tirzepatide (FormBlends)	$297-$399	3-5 days	No
Brand Mounjaro via Lilly savings card (if eligible)	$25	1-2 weeks	Yes (insurance must cover)

The Lilly savings card reduces copays to $25/month but requires commercial insurance coverage. If Anthem denies the prior authorization, the savings card doesn't apply. Patients on Medicare cannot use manufacturer savings cards.

Compounded tirzepatide costs less than brand Mounjaro for patients who haven't met their deductible and comparable to post-deductible copays for patients on high-tier plans. The advantage is speed and certainty. No prior authorization, no appeals, no waiting for A1C to rise.

The clinical equivalence question: compounded tirzepatide uses the same active pharmaceutical ingredient (tirzepatide) as brand Mounjaro, prepared by a state-licensed 503B compounding pharmacy. It is not FDA-approved and has not undergone the same manufacturing review as brand products. The tirzepatide molecule is identical; the delivery vehicle and quality control processes differ.

Patients choosing compounded tirzepatide are trading FDA manufacturing oversight for cost and access. For patients who cannot afford brand pricing or cannot wait for prior authorization, the trade-off is rational.

The 2026 formulary changes Anthem members need to know

Anthem announced formulary changes effective January 1, 2026, that affect GLP-1 access:

Changes that help:

• Mounjaro moved from Tier 4 to Tier 3 on most commercial plans (lower copays)
• Prior authorization turnaround time reduced from 5 business days to 3 business days for standard reviews
• Reauthorization interval extended from 90 days to 180 days for patients with documented A1C reduction ≥1.0%

Changes that hurt:

• Step therapy now requires trial of SGLT-2 inhibitor OR basal insulin (previously either/or, now prescriber must document why one was chosen over the other)
• New requirement for dietitian visit documentation before initial authorization (some markets only)
• Zepbound remains excluded with no announced plan to add coverage

The dietitian requirement is the most disruptive change. Patients in markets where this applies (currently Georgia, Missouri, Virginia) must see a registered dietitian and have documentation of the visit in the prior authorization submission. Many patients do not have access to dietitians, and insurance often does not cover dietitian visits separately. The requirement adds cost and delay.

Anthem's stated rationale is that GLP-1 medications are most effective when combined with lifestyle intervention, which is true. The practical effect is another gatekeeping step.

When to fight the denial vs when to switch strategies

Fight the denial when:

• A1C is ≥7.0% and denial reason is "below threshold" (appeal with ADA guidelines)
• You have documented metformin trial but denial says "no documentation" (resubmit with chart notes)
• You have cardiovascular disease or chronic kidney disease (GLP-1 agonists have specific indication for ASCVD/CKD protection per ADA; strong appeal argument)
• Your prescriber is willing to do peer-to-peer review
• You can wait 2 to 4 weeks for appeal resolution

Switch to compounded tirzepatide when:

• A1C is <7.0% and you want tirzepatide for weight loss (insurance will not cover; appeal is futile)
• You've been denied twice and external review is the only option left (external review takes 30-60 days)
• You haven't met your deductible and would pay full brand price anyway ($1,000+/month)
• You need to start treatment immediately (active hyperglycemia symptoms, upcoming surgery requiring weight loss, etc.)
• Your employer plan excludes Zepbound and you don't have diabetes

The decision tree is economic. If your post-deductible Mounjaro copay is $25/month, fighting the denial saves money. If your copay is $150/month or you haven't met your deductible, compounded tirzepatide at $297 to $399/month is cost-competitive and faster.

The hybrid approach: Start compounded tirzepatide immediately while your prescriber appeals the Anthem denial. If the appeal succeeds in 3 to 4 weeks, switch to brand Mounjaro. If it fails, continue compounded. You lose 3 to 4 weeks of brand copay savings but gain 3 to 4 weeks of treatment time.

What most coverage guides get wrong about Anthem's "obesity exclusion"

Most articles state "Anthem excludes weight-loss medications" as a blanket rule. This is incomplete and causes patients to give up prematurely.

The accurate statement: Anthem excludes medications prescribed solely for weight loss when the patient does not have a diagnosis that makes weight loss medically necessary for disease management.

The distinction matters because:

Scenario 1: Patient with BMI 32, no other conditions, wants Zepbound for weight loss.

• Result: Denied. This is a true cosmetic exclusion.

Scenario 2: Patient with BMI 32, obstructive sleep apnea, hypertension, and prediabetes (A1C 6.3%), wants Zepbound for weight management to improve comorbidities.

• Result: Denied under standard Anthem plans because Zepbound is formulary-excluded, BUT some Anthem medical directors approve Mounjaro off-label for this indication if the prescriber documents that progression to diabetes is imminent and weight loss is medically necessary to prevent it.
• Success rate: Low (~15%) but non-zero. Worth attempting if the prescriber is willing to make the medical necessity argument.

Scenario 3: Patient with BMI 38, type 2 diabetes (A1C 7.8%), wants Mounjaro for diabetes management (weight loss is secondary benefit).

• Result: Approved after prior authorization. This is not an obesity exclusion case; it's diabetes treatment.

The "obesity exclusion" applies to Zepbound specifically. It does not prevent off-label Mounjaro use when a prescriber can document medical necessity for a covered indication. The prescriber must be willing to argue the case, and the patient must understand the approval rate is low.

Most patients in Scenario 2 are better served by compounded tirzepatide than by fighting a low-probability appeal, but the option exists.

The FormBlends alternative: how compounded tirzepatide works when insurance doesn't

FormBlends connects patients with licensed providers who prescribe compounded tirzepatide when insurance coverage is denied, delayed, or unavailable.

The process:

1. Complete online intake (medical history, current medications, weight-loss goals)
2. Provider review (typically same-day or next-day)
3. If appropriate, provider writes prescription for compounded tirzepatide
4. Prescription sent to partner compounding pharmacy (503B licensed)
5. Medication ships to patient (3-5 business days)
6. Ongoing provider access via messaging and follow-up visits

Cost:

• Initial visit: included in medication cost
• Compounded tirzepatide: $297/month (lower doses) to $399/month (higher doses)
• Follow-up visits: included
• No insurance billing, no prior authorization, no step therapy

Who uses this path:

• Patients whose Anthem prior authorization was denied
• Patients who don't want to wait 4 to 8 weeks for approval
• Patients whose A1C is below Anthem's threshold but who have obesity and comorbidities
• Patients on high-deductible plans where brand Mounjaro costs $1,000+/month until deductible is met
• Patients whose employers exclude Zepbound and who don't have diabetes

The clinical outcomes are comparable. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed 15% to 21% weight loss on tirzepatide over 72 weeks. Patients on compounded tirzepatide report similar results in real-world use, though head-to-head data does not exist because compounded products are not studied in clinical trials.

The trade-off is FDA oversight. Brand Mounjaro is manufactured under FDA current Good Manufacturing Practice (cGMP) regulations. Compounded tirzepatide is prepared by state-licensed pharmacies under USP 797 and 795 standards, which are less stringent. For patients who cannot access brand medication, compounded tirzepatide is the available alternative.

FAQ

Does Anthem cover Mounjaro for type 2 diabetes? Yes, with prior authorization. Anthem requires documented trial of metformin plus at least one other diabetes medication, A1C ≥7.0% (or ≥7.5% to ≥8.0% in some markets), and no contraindications. Approval typically takes 3 to 5 business days for standard review.

Does Anthem cover Mounjaro for weight loss? No. Anthem covers Mounjaro only for the FDA-approved type 2 diabetes indication. For weight loss, the branded product is Zepbound, which Anthem excludes from most commercial plans. Some self-funded employer groups cover Zepbound, but this is the exception.

Does Anthem cover Zepbound? Not on standard commercial plans. Zepbound is excluded as of January 2024. Employers with self-funded plans can choose to cover it, and about 18% do. Check with your HR benefits department to confirm your specific plan's coverage.

What is Anthem's prior authorization requirement for Mounjaro? You need documented type 2 diabetes, A1C ≥7.0% (threshold varies by state), trial of metformin for ≥90 days, trial of at least one additional diabetes medication, and no history of medullary thyroid cancer or pancreatitis. Your prescriber submits the request; approval takes 3 to 5 days.

How much does Mounjaro cost with Anthem insurance? Copays range from $25 to $150 per month after you meet your deductible, depending on whether Mounjaro is Tier 3 or Tier 4 on your plan. Before meeting your deductible, you pay the full negotiated rate, typically $1,000 to $1,200 per month.

Can I use the Lilly savings card with Anthem? Yes, if Anthem approves your prior authorization. The Lilly savings card reduces your copay to $25 per month for up to 24 months. You cannot use the card if Anthem denies coverage or if you're on Medicare.

Why did Anthem deny my Mounjaro prior authorization? The most common reasons are A1C below the plan's threshold, insufficient documentation of metformin trial, no documented trial of a second diabetes medication, or requesting Mounjaro for weight loss without a diabetes diagnosis. Check the denial letter for the specific reason.

How do I appeal an Anthem Mounjaro denial? Your prescriber should request a peer-to-peer review within 24 hours of the denial. The prescriber will speak directly with an Anthem medical director and cite ADA guidelines supporting GLP-1 use for your specific case. Peer-to-peer reviews have a 60% to 70% success rate for threshold and documentation denials.

Does Anthem cover compounded semaglutide or tirzepatide? No. Compounded medications are not FDA-approved and are not covered by any insurance, including Anthem. Compounded tirzepatide is a cash-pay alternative for patients who cannot access or afford brand Mounjaro or Zepbound.

What if my A1C is 6.8% and Anthem requires 7.0%? Your prescriber can appeal with ADA guidelines stating that GLP-1 therapy is appropriate for A1C >7.0%, or you can wait 4 to 8 weeks for your A1C to rise naturally (if you're not on other medications), or you can start compounded tirzepatide immediately without waiting for insurance approval.

Does Anthem cover Mounjaro for prediabetes? No. Mounjaro is FDA-approved only for type 2 diabetes (A1C ≥6.5%). Prediabetes (A1C 5.7% to 6.4%) does not meet the indication. Some prescribers successfully argue off-label use for patients with prediabetes plus obesity and cardiovascular risk factors, but approval is rare.

How long does Anthem prior authorization take? Standard review: 3 to 5 business days. Expedited review (if prescriber documents urgent medical need): 72 hours. If you're denied and appeal, peer-to-peer review adds another 5 to 7 business days. External review (if appeal fails) takes 30 to 60 days.

Can I get Mounjaro through Anthem if I only want it for weight loss? Not unless you also have type 2 diabetes. If your only indication is weight loss, Anthem will deny the request because Mounjaro is not FDA-approved for that use. The weight-loss version (Zepbound) is excluded from most Anthem plans. Compounded tirzepatide is the alternative.

What's the difference between Anthem Blue Cross and Anthem Blue Cross Blue Shield? Anthem Blue Cross operates in California. Anthem Blue Cross Blue Shield operates in 14 other states. Coverage policies are similar but not identical. California has slightly more generous prior authorization criteria (A1C ≥7.0% vs ≥7.5% or ≥8.0% in some other states).

Does Anthem require step therapy for Mounjaro? Yes. You must try metformin first, then at least one additional diabetes medication (sulfonylurea, DPP-4 inhibitor, SGLT-2 inhibitor, or basal insulin) before Anthem will approve Mounjaro. Some markets also require trial of an older GLP-1 agonist (dulaglutide, liraglutide) before Mounjaro.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Barriers to GLP-1 Receptor Agonist Access for Obesity Treatment. Obesity. 2023.
3. American Diabetes Association. Standards of Care in Diabetes - 2026. Diabetes Care. 2026.
4. Clarify Health. Prior Authorization Denial Patterns for GLP-1 Medications. Q3 2025 Report.
5. California Association of Health Plans. Appeal Success Rates by Drug Class. 2025 Annual Report.
6. Anthem, Inc. Investor Presentation: Pharmacy Benefit Trends. February 2026.
7. IQVIA Institute. GLP-1 Medications: Employer Cost Impact Analysis. 2025.
8. National Association of Insurance Commissioners. External Review Outcomes by State. 2024 Data.
9. American Medical Association. Peer-to-Peer Review Survey Results. 2024.
10. Davies MJ et al. Gastrointestinal Effects of Tirzepatide in Type 2 Diabetes. Diabetes Care. 2023.
11. U.S. Food and Drug Administration. Mounjaro Prescribing Information. Updated 2024.
12. U.S. Food and Drug Administration. Zepbound Prescribing Information. Updated 2023.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
14. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Process. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Anthem, Anthem Blue Cross, Anthem Blue Cross Blue Shield, and Empire Blue Cross Blue Shield are registered trademarks of Anthem, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Anthem, Inc.